These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 22406621)

  • 41. The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation.
    Liu X; Yuan H; Peres L; Chen S; Chen Z; de The H; Zhou J; Zhu J
    PLoS One; 2014; 9(8):e104906. PubMed ID: 25119106
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human Regulatory Protein Ki-1/57 Is a Target of SUMOylation and Affects PML Nuclear Body Formation.
    Saito Â; Souza EE; Costa FC; Meirelles GV; Gonçalves KA; Santos MT; Bressan GC; McComb ME; Costello CE; Whelan SA; Kobarg J
    J Proteome Res; 2017 Sep; 16(9):3147-3157. PubMed ID: 28695742
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.
    Liu J; Zhu HH; Jiang H; Jiang Q; Huang XJ
    Blood; 2016 Jan; 127(2):243-50. PubMed ID: 26537301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML.
    Weisshaar SR; Keusekotten K; Krause A; Horst C; Springer HM; Göttsche K; Dohmen RJ; Praefcke GJ
    FEBS Lett; 2008 Sep; 582(21-22):3174-8. PubMed ID: 18708055
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ubiquitin-SUMO circuitry controls activated fanconi anemia ID complex dosage in response to DNA damage.
    Gibbs-Seymour I; Oka Y; Rajendra E; Weinert BT; Passmore LA; Patel KJ; Olsen JV; Choudhary C; Bekker-Jensen S; Mailand N
    Mol Cell; 2015 Jan; 57(1):150-64. PubMed ID: 25557546
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantitative SUMO proteomics identifies PIAS1 substrates involved in cell migration and motility.
    Li C; McManus FP; Plutoni C; Pascariu CM; Nelson T; Alberici Delsin LE; Emery G; Thibault P
    Nat Commun; 2020 Feb; 11(1):834. PubMed ID: 32047143
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In situ SUMOylation analysis reveals a modulatory role of RanBP2 in the nuclear rim and PML bodies.
    Saitoh N; Uchimura Y; Tachibana T; Sugahara S; Saitoh H; Nakao M
    Exp Cell Res; 2006 May; 312(8):1418-30. PubMed ID: 16688858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SUMO3 modification by PIAS1 modulates androgen receptor cellular distribution and stability.
    Yang N; Liu S; Qin T; Liu X; Watanabe N; Mayo KH; Li J; Li X
    Cell Commun Signal; 2019 Nov; 17(1):153. PubMed ID: 31752909
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Linking nuclear matrix-localized PIAS1 to chromatin SUMOylation via direct binding of histones H3 and H2A.Z.
    Chen Z; Zhang Y; Guan Q; Zhang H; Luo J; Li J; Wei W; Xu X; Liao L; Wong J; Li J
    J Biol Chem; 2021 Oct; 297(4):101200. PubMed ID: 34537242
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation.
    Gao C; Ho CC; Reineke E; Lam M; Cheng X; Stanya KJ; Liu Y; Chakraborty S; Shih HM; Kao HY
    Mol Cell Biol; 2008 Sep; 28(18):5658-67. PubMed ID: 18625722
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The SUMO2/3 specific E3 ligase ZNF451-1 regulates PML stability.
    Koidl S; Eisenhardt N; Fatouros C; Droescher M; Chaugule VK; Pichler A
    Int J Biochem Cell Biol; 2016 Oct; 79():478-487. PubMed ID: 27343429
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML.
    Hirano S; Tadano M; Kobayashi Y; Udagawa O; Kato A
    Toxicol Appl Pharmacol; 2015 Sep; 287(3):191-201. PubMed ID: 26049103
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability.
    Yang WC; Shih HM
    Oncogene; 2013 Oct; 32(43):5167-75. PubMed ID: 23208507
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PIAS1-mediated sumoylation promotes STUbL-dependent proteasomal degradation of the human telomeric protein TRF2.
    Her J; Jeong YY; Chung IK
    FEBS Lett; 2015 Oct; 589(21):3277-86. PubMed ID: 26450775
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
    Sternsdorf T; Puccetti E; Jensen K; Hoelzer D; Will H; Ottmann OG; Ruthardt M
    Mol Cell Biol; 1999 Jul; 19(7):5170-8. PubMed ID: 10373566
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
    Kunapuli P; Kasyapa CS; Chin SF; Caldas C; Cowell JK
    Exp Cell Res; 2006 Nov; 312(19):3739-51. PubMed ID: 17027752
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The p97/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA.
    Jaffray EG; Tatham MH; Mojsa B; Liczmanska M; Rojas-Fernandez A; Yin Y; Ball G; Hay RT
    J Cell Biol; 2023 Apr; 222(4):. PubMed ID: 36880596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities.
    Ibata M; Iwasaki J; Fujioka Y; Nakagawa K; Darmanin S; Onozawa M; Hashimoto D; Ohba Y; Hatakeyama S; Teshima T; Kondo T
    Cancer Sci; 2017 Feb; 108(2):200-207. PubMed ID: 27960034
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phosphorylation-dependent interaction of SATB1 and PIAS1 directs SUMO-regulated caspase cleavage of SATB1.
    Tan JA; Song J; Chen Y; Durrin LK
    Mol Cell Biol; 2010 Jun; 30(11):2823-36. PubMed ID: 20351170
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.
    Dos Santos GA; Kats L; Pandolfi PP
    J Exp Med; 2013 Dec; 210(13):2793-802. PubMed ID: 24344243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.